Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 162 results for "Tecfidera Treated Patients"

Tecfidera demonstrates sustained efficacy in RRMS studies
European Pharmaceutical Review

TECFIDERA® data highlights benefit of early treatment in rela...

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ... Hospital Pharmacy Europe, 1 day ago
Tecfidera demonstrates sustained efficacy in RRMS studies European Pharmaceutical Review, 1 week ago
[x]  
PRWeb

Medicationdiscountcard.com Provides Prescription Coupons to Patients With Multiple Sclerosis: In Tandem With New Treatments

Presription Savings Card Atlantic City, NJ (PRWEB) April 19, 2016 Over 400,000 Americans live with Multiple Sclerosis (MS) every day. There are an estimated 10,000 new cases diagnosed each year. New therapies that slow the progression of ...
 PRWeb1 week ago

EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® (interferon beta-1a) vs. TECFIDERA® (dimethyl fumurate) at AAN Annual Meeting

_ A real-world assessment of relapse rates in patients with MS newly initiating self-injectable treatment with Rebif versus an oral disease-modifying therapy, as well as the clinical effect of Rebif on 'no evident disease activity' (NEDA) and MRI ...
 Sys-Con Media2 weeks ago
[x]  

Controlling complicated psoriasis

Dermatologists and their patients have benefited immensely from the expanded armamentarium of treatment options for plaque psoriasis. Nevertheless, they may still be challenged by patients with coexisting systemic diseases or other psoriasis ...
 Dermatology Times3 weeks ago

Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16

Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ...
 Yahoo! Finance UK and Ireland4 days ago
[x]  
TheStreet.com

New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's...

New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's Tecfidera, Novartis' Gilenya And Sanofi's Aubagio By a News Reporter-Staff News Editor at Pharma ...
 Equities.com1 week ago
[x]  
Livemint.com

Dr Reddy's enters into licensing pact with US-based XenoPort

Dr. Reddy's will develop and market XenoPort's new chemical entity to treat plaque psoriasis and multiple sclerosis for the US market Hyderabad: Dr. Reddy's Laboratories Ltd, India's second largest drug maker, on Monday said it has entered into a ...
 Livemint.com1 month ago Forming pact for psoriasis drug development with Xenoport  Nikkei Asian Review1 month ago Dr Reddy's enters into in-licensing pact with US-based XenoPort [Mint, New Delhi]  Bloomberg1 month ago

Tecfidera Revenues Expected to Boost Biogen's 2016 Valuations

Drugs That Could Boost Biogen's Valuations in 2016 ( Continued from Prior Part ) Tecfidera revenues Biogen Idec (BIIB) saw a sudden revenue decline for Tecfidera in 2015. But demand for the drug in the US market is expected to remain stable ...
 Yahoo! Singapore2 months ago Alzheimer's Research Is Still Key Driver of Biogen's Valuations  Yahoo! Finance UK and Ireland1 month ago
[x]  

Tecfidera (dimethyl fumarate)

Label Changes for: February 2016 Changes have been made to the WARNINGS and PRECAUTIONS sections of the safety label. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) February 2016 ...
 Drugs.com1 month ago
Advance For NPs And PAs

Treatment Strategies for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, often progressive disease of the central nervous system (CNS) that is a leading cause of disability in young adults; the median age of onset is 30. 1,2 The etiology of MS is unknown, but it is believed to ...
 Advance For NPs And PAs1 month ago Treating Multiple Sclerosis: Oral Therapy Comes of Age  Monthly Prescribing Reference1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less